



(19) REPUBLIKA HRVATSKA
DRŽAVNI ZAVOD ZA
INTELEKTUALNO VLASNIŠTVO

(10) Identifikator
dokumenta:

HR P20201692 T1



HR P20201692 T1

(12) **PRIJEVOD PATENTNIH ZAHTEJEVA
EUROPSKOG PATENTA**

(51) MKP:

C07K 7/08 (2006.01)
C07K 7/56 (2006.01) **G01N 33/68** (2006.01)
A61K 38/12 (2006.01) **A61P 37/06** (2006.01)

(46) Datum objave prijevoda patentnih zahtjeva: 25.12.2020.

(21) Broj predmeta: P20201692T

(22) Datum podnošenja zahtjeva u HR: 20.10.2020.

(86) Broj međunarodne prijave: PCT/US2015060265
Datum podnošenja međunarodne prijave: 12.11.2015.

(96) Broj europske prijave patenta: EP 15801052.0
Datum podnošenja europske prijave patenta: 12.11.2015.

(87) Broj međunarodne objave: WO 2016077518
Datum međunarodne objave: 19.05.2016.

(97) Broj objave europske prijave patenta: EP 3218392 A1
Datum objave europske prijave patenta: 20.09.2017.

(97) Broj objave europskog patenta: EP 3218392 B1
Datum objave europskog patenta: 29.07.2020.

(31) Broj prve prijave: 201462079944 P (32) Datum podnošenja prve prijave: 14.11.2014. (33) Država ili organizacija podnošenja prve prijave: US
201562111388 P 03.02.2015. US
201562204689 P 13.08.2015. US

(73) Nositelj patenta:

Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, NJ 08543, US

(72) Izumitelji:

Kevin W. Gillman, c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, CT 06492, US
Jason Goodrich, c/o Bristol Myers Squibb Company, 5 Research Parkway, Wallingford, CT 06492, US
Kenneth M. Boy, c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, CT 06492, US
Yunhui Zhang, c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, CT 06492, US
Claudio Mapelli, 465 Briggs Road, Langhorne, PA 19047, US
Michael A. Poss, c/o Bristol-Myers Squibb Company, Route 206 & Province Line Road, Princeton, NJ 08543, US
Li-Qiang Sun, c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, CT 06492, US
Qian Zhao, 93 Hintz Drive, Wallingford, CT 06492, US
Eric Mull, c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, CT 06492, US
Eric P. Gillis, c/o Bristol-Myers Squibb Company 5 Research Parkway, Wallingford, CT 06492, US
Paul Michael Scola, c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, CT 06492, US
David R. Langley, c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, CT 06492, US
M. Nicholas Meanwell, c/o Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, NJ 08543, US
Odvjetnica Gorana Grubišić, dipl.iur., 10000 Zagreb, HR


(74) Zastupnik:

(54) Naziv izuma: **MAKROCIKLIČNI PEPTIDI KORISNI KAO IMUNOMODULATORI**

HR P20201692 T1


PATENTNI ZAHTJEVI

1. Spoj sa formulom (I)




(I),

ili farmaceutski prihvatljiva sol istog, gdje:
A je odabrano od



gdje:

- $\sim^*$ označava točku vezivanja sa karbonil grupom i $\sim^*$
 označava točku vezivanja sa atomom dušika;
 n je 0 ili 1;
 m je 1 ili 2;
 m' je 0 ili 1;
 w je 0, 1, ili 2;
 R^x je odabrano od vodika, amino, hidroksi, i metila;
 R^{14} i R^{15} su nezavisno odabrani od vodika i metila;
 R^{16a} je odabrano od vodika i C_1-C_6 alkila;
 R^{16} je odabrano od
 $-(C(R^{17a})_2)_2-X-R^{30}$,



gdje:

w' je 2 ili 3;

n' je 1-6;

m' je 0-5;

X je lanac od između 1 i 172 atoma gdje su atomi odabrani od ugljika i kisika i gdje lanac može da sadrži jednu, dvije, tri, ili četiri grupe odabrane od -NHC(O)NH-, i -C(O)NH- ugrađene tamo; i gdje je lanac po izboru supstituiran sa jednom do šest grupa nezavisno odabranih od -CO₂H, -C(O)NH₂, -CH₂C(O)NH₂, i - (CH₂)CO₂H;


X' je lanac od između 1 i 172 atoma gdje su atomi odabrani od ugljika i kisika i gdje lanac može da sadrži jednu, dvije, tri, ili četiri grupe odabrane od -NHC(O)NH-, i -C(O)NH- ugrađene tamo; i gdje je lanac po izboru supstituiran sa jednom do šest grupa nezavisno odabranih od -CO₂H, -C(O)NH₂, i -CH₂CO₂H, pod uvjetom da X' je drugačije od nesupstituiranog PEG;

R³⁰ je odabrano od -CO₂H, -C(O)NR^wR^x, i -CH₃ gdje R^w i R^x su nezavisno odabrani od vodika i C₁-C₆alkila, pod uvjetom da kada X je sav ugljik, R³⁰ je drugačije od -CH₃;

R³¹ je -CO₂H, -C(O)NR^wR^x, -CH₃, aleksa-5-SDP, i biotin;

svako R^{17a} je nezavisno odabrano od vodika, C₁-C₆alkila, -CH₂OH, -CH₂CO₂H, -(CH₂)₂CO₂H,

svako R¹⁷ je nezavisno odabrano od vodika, -CH₃, (CH₂)_zN₃, -(CH₂)_zNH₂, -X-R³¹, -(CH₂)_zCO₂H, -CH₂OH, CH₂C≡CH, i -(CH₂)_z-triazolil-X-R³⁵, gdje z je 1-6 i R³⁵ je odabrano od -CO₂H, -C(O)NR^wR^x, CH₃, biotina, -2-fluoripiridina, -C(O)-(CH₂)₂-C(O)O-vitamina E, -C(O)O-vitamina E; i



pod uvjetom da je najmanje jedno R¹⁷ drugačije od vodika, -CH₃, ili -CH₂OH;

R^c, R^f, R^h, Rⁱ, R^m, i Rⁿ su vodik;

R^a, R^e, R^j, i R^k, su svako nezavisno odabrano od vodika i metila;

R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², i R¹³ su nezavisno odabrani od bočnog lanca prirodne amino kiseline i bočnog lanca ne-prirodne amino kiseline ili formiraju prsten sa odgovarajućom susjednom R grupom kao što je opisano ispod;

R^e i R^k svako, može da formira prsten sa odgovarajućom susjednom R grupom i atomima za koje su povezani odabran od azetidina, pirolidina, morfolina, piperidina, piperazina, i tetrahidrotiazola; gdje svaki prsten je po izboru supstituiran sa jednom do četiri grupe nezavisno odabrane od amino, cijano, metil, halo, i hidroksi;


R^b je metil ili, R^b i R², zajedno sa atomima za koje su vezani, formiraju prsten odabran od azetidina, pirolidina, morfolina, piperidina, piperazina, i tetrahidrotiazola; gdje svaki prsten je po izboru supstituiran sa jednom do četiri grupe nezavisno odabrane od amino, cijano, metil, halo, i hidroksi;

R^d je vodik ili metil, ili, R^d i R⁴, zajedno sa atomima za koje su vezani, mogu formirati prsten odabran od azetidina, pirolidina, morfolina, piperidina, piperazina, i tetrahidrotiazola; gdje svaki prsten je po izboru supstituiran sa jednom do četiri grupe nezavisno odabrane od amino, cijano, metil, halo, hidroksi, i fenil;

R^g je vodik ili metil ili R^g i R⁷, zajedno sa atomima za koje su vezani, mogu formirati prsten odabran od azetidina, pirolidina, morfolina, piperidina, piperazina, i tetrahidrotiazola; gdje svaki prsten je po izboru supstituiran sa jednom do četiri grupe nezavisno odabrane od amino, benzil po izboru supstituirane sa halo grupom, benziloksi, cijano, cikloheksil, metil, halo, hidroksi, izohinoliniloksi po izboru supstituirane sa halo grupom, metoksi grupom, hinoliniloksi po izboru supstituirane sa halo grupom, i tetrazolil; i gdje pirolidinski i piperidinski prsten su po izboru fuzionirani sa cikloheksil, fenil, ili indol grupom; i

R¹ je metil ili, R¹ i R¹², zajedno sa atomima za koje su vezani, formiraju prsten odabran od azetidina i pirolidina, gdje svaki prsten je po izboru supstituiran sa jednom do četiri nezavisno odabrane od amino, cijano, metil, halo, i hidroksi.


2. Spoj iz patentnog zahtjeva 1, ili farmaceutski prihvatljiva sol istog, gdje A je



3. Spoj iz patentnog zahtjeva 2, ili farmaceutski prihvatljiva sol istog, gdje: m i w su 1; i

R^{14} , R^{15} , i R^{16a} su svako vodik.

4. Spoj iz patentnog zahtjeva 3, ili farmaceutski prihvatljiva sol istog, gdje R^{16} je $-(C(R^{17a})_2)_2-X-R^{30}$.
5. Spoj iz patentnog zahtjeva 4, ili farmaceutski prihvatljiva sol istog, gdje:
 - svako R^{17a} je vodik;
 - X je lanac od između 8 i 46 atoma gdje su atomi odabrani od ugljika i kisika i gdje lanac može da sadrži jednu, dvije, ili tri $C(O)NH$ grupe ugrađene tamo; i gdje lanac je po izboru supstituiran sa jednom ili dvije grupe nezavisno odabrane od $-CO_2H$, $-C(O)NH_2$, $-CH_2C(O)NH_2$, i $-CH_2CO_2H$; i
 - R^{30} je odabrano od $-CH_3$, $-CO_2H$, i $-C(O)NH_2$; pod uvjetom da kada X je sav ugljik, R^{30} je drugačije od $-CH_3$.
6. Spoj iz patentnog zahtjeva 3, ili farmaceutski prihvatljiva sol istog, gdje R^{16} je $-C(R^{17a})_2C(O)N(R^{16a})C(R^{17a})_2-X'-R^{31}$.
7. Spoj iz patentnog zahtjeva 6, ili farmaceutski prihvatljiva sol istog, gdje
 - svako R^{17a} je odabrano od vodika, $-CO_2H$, i $-CH_2CO_2H$;
 - X' je lanac od između 8 i 48 atoma gdje su atomi odabrani od ugljika i kisika i gdje lanac može da sadrži jednu, dvije, ili tri $C(O)NH$ grupe ugrađene tamo; i gdje lanac je po izboru supstituiran sa jednom ili dvije grupe nezavisno odabrane od $-CO_2H$, $-C(O)NH_2$, $-CH_2C(O)NH_2$, i $-CH_2CO_2H$; pod uvjetom da X' je drugačije od nesupstituiranog PEG; i
 - R^{30} je odabrano od $-CH_3$, $-CO_2H$, i $-C(O)NH_2$.
8. Spoj iz patentnog zahtjeva 3, ili farmaceutski prihvatljiva sol istog, gdje R^{16} je $-C(R^{17a})_2[C(O)N(R^{16a})C(R^{17a})_2]_w-X'-R^{31}$.
9. Spoj iz patentnog zahtjeva 8, ili farmaceutski prihvatljiva sol istog, gdje
 - svako R^{17a} je odabrano od vodika, $-CO_2H$, i $-CH_2CO_2H$;
 - X je lanac od između 8 i 48 atoma gdje su atomi odabrani od ugljika i kisika i gdje lanac može da sadrži jednu, dvije, ili tri $C(O)NH$ grupe ugrađene tamo; i gdje lanac je po izboru supstituiran sa jednom ili dvije grupe nezavisno odabrane od $-CO_2H$, $-C(O)NH_2$, $-CH_2C(O)NH_2$, i $-CH_2CO_2H$; i
 - R^{31} je odabrano od $-CH_3$, $-CO_2H$, i $-C(O)NH_2$.
10. Spoj iz patentnog zahtjeva 3, ili farmaceutski prihvatljiva sol istog, gdje R^{16} je $-(C(R^{17a})(R^{17})C(O)NR^{16a})_n-H$.
11. Spoj iz patentnog zahtjeva 10, ili farmaceutski prihvatljiva sol istog, gdje
 - svako R^{17a} je vodik; i
 - svako R^{17} je odabrano od vodika, $-CH_3$, $(CH_2)_zN_3$, $-(CH_2)_zNH_2$, $-X-R^{31}$, $-(CH_2)_zCO_2H$, $-CH_2OH$, $CH_2C\equiv CH$, i $-(CH_2)_z$ -triazolil- $X-R^{35}$; pod uvjetom da je najmanje jedno R^{17} drugačije od vodika, $-CH_3$, ili $-CH_2OH$; z je 1-4;
 - R^{31} je odabrano od $-CH_3$, $-CO_2H$, i $-C(O)NH_2$;
 - X je lanac od između 7 i 155 atoma gdje su atomi odabrani od ugljika i kisika i gdje lanac može da sadrži jednu, dvije, ili tri $C(O)NH$ grupe ugrađene tamo; i gdje lanac je po izboru supstituiran sa jednom ili dvije grupe nezavisno odabrane od $-CO_2H$, $-C(O)NH_2$, $-CH_2C(O)NH_2$, i $-CH_2CO_2H$; i
 - R^{35} je odabrano od $-CO_2H$, $-C(O)NR^wR^x$, CH_3 , biotina, -2-fluoripiridina, $-C(O)-(CH_2)_2-C(O)O$ -vitamina E, i $-C(O)O$ -vitamina E.
12. Spoj iz patentnog zahtjeva 3, ili farmaceutski prihvatljiva sol istog, gdje R^{16} je $-(CR^{17a})(R^{17})C(O)NR^{16a})_m-C(R^{17a})(R^{17})-CO_2H$.
13. Spoj iz patentnog zahtjeva 12, ili farmaceutski prihvatljiva sol istog, gdje
 - m' je 1-3;
 - svako R^{17a} je vodik;
 - svako R^{17} je odabrano od vodika, $-CH_3$, $(CH_2)_zN_3$, $-(CH_2)_zNH_2$, $-X-R^{31}$, $-(CH_2)_zCO_2H$, $-CH_2OH$, $CH_2CC\equiv CH$, $-(CH_2)_z$ -triazolil- $X-R^{35}$, i $C(O)O$ -vitamina E; i



pod uvjetom da je najmanje jedno R^{17} drugačije od vodika, $-CH_3$, ili $-CH_2OH$;

z je 1-4;

R^{31} je odabrano od $-CH_3$, $-CO_2H$, i $-C(O)NH_2$;

X je lanac od između 20 i 60 atoma gdje su atomi odabrani od ugljika i kisika i gdje lanac može da sadrži jednu, dvije, ili tri $C(O)NH$ grupe ugrađene tamo; i gdje lanac je po izboru supstituiran sa jednom ili dvije grupe nezavisno odabrane od $-CO_2H$, $-C(O)NH_2$, $-CH_2C(O)NH_2$, i $-CH_2CO_2H$; i

R^{35} je odabrano od $-CO_2H$, $-C(O)NR^wR^x$, CH_3 , biotina, 2-fluoripiridina, $-C(O)-(CH_2)_2-C(O)O$ -vitamina E, i $-C(O)O$ -vitamina E.

14. Spoj iz patentnog zahtjeva 2, ili farmaceutski prihvatljiva sol istog, gdje R^1 je fenil- C_1 - C_3 alkil gdje fenil dio je po izboru supstituiran sa hidroksil, halo, ili metoksi; R^2 je C_1 - C_7 alkil ili, R^2 i R^b , zajedno sa atomima za koje su vezani, formiraju piperidinski prsten; R^3 je $NR^xR^y(C_1-C_7$ alkil), NR^uR^v karbonil- C_1 - C_3 alkil, ili karboksi- C_1 - C_3 alkil; R^4 i R^d , zajedno sa atomima za koje su vezani, formiraju pirolidinski prsten; R^5 je hidroksi- C_1 - C_3 alkil, imidazolil- C_1 - C_3 alkil, ili $NR^xR^y(C_1-C_7$ alkil); R^6 je karboksi- C_1 - C_3 alkil, NR^uR^v karbonil- C_1 - C_3 alkil, $NR^xR^y(C_1-C_7$ alkil), ili C_1 -

C₇alkil; R⁷ i R⁸, zajedno sa atomima za koje su vezani, formiraju pirolidinski prsten po izboru supstituiran sa hidroksi; R⁸ i R¹⁰ su benzotienil ili indolilC₁-C₃alkil po izboru supstituiran sa karboksic₁-C₃alkil; R⁹ je hidroksiC₁-C₃alkil, aminoC₁-C₃alkil, ili C₁-C₇alkil, R¹¹ je C₁-C₃alkoksiC₁-C₃alkil ili C₁-C₇alkil; R¹² je C₁-C₇alkil ili hidroksiC₁-C₃alkil; i R¹³ je C₁-C₇alkil, karboksic₁-C₃alkil, ili -(CH₂)₃NHC(NH)NH₂.


15. Spoj iz patentnog zahtjeva 2, ili farmaceutski prihvatljiva sol istog, gdje:

R^d je metil ili, R^d i R⁴, zajedno sa atomima za koje su vezani, formiraju prsten odabran od azetidina, pirolidina, morfolina, piperidina, piperazina, i tetrahidrotiazola; gdje svaki prsten je po izboru supstituiran sa jednom ili dvije grupe nezavisno odabrane od amino, cijano, metil, halo, hidroksi, i fenil;

R^g je metil ili, R^g i R⁷, zajedno sa atomima za koje su vezani, formiraju prsten odabran od azetidina, pirolidina, morfolina, piperidina, piperazina, i tetrahidrotiazola; gdje svaki prsten je po izboru supstituiran sa jednom ili dvije grupe nezavisno odabrane od amino, benzil po izboru supstituirane sa halo grupom, benziloksi, cijano, cikloheksil, metil, halo, hidroksi, izohinoliniloksi po izboru supstituirane sa metoksi grupom, hinoliniloksi po izboru supstituirane sa halo grupom, i tetrazolil; i gdje pirolidinski i piperidinski prsten su po izboru fuzionirani sa cikloheksil, fenil, ili indol grupom; i

R^k je metil ili, R^k i R¹¹, zajedno sa atomima za koje su vezani, formiraju prsten odabran od azetidina, pirolidina, morfolina, piperidina, piperazina, i tetrahidrotiazola; gdje svaki prsten je po izboru supstituiran sa jednom ili dvije grupe nezavisno odabrane od amino, cijano, metil, halo, i hidroksi.


16. Spoj sa formulom (II)



(II),

ili farmaceutski prihvatljiva sol istog, gdje:

A je odabrano od



gdje:

n je 0 ili 1;

R¹⁴ i R¹⁵ su nezavisno odabrani od vodika i metila;

R^{16a} je odabrano od vodika i C₁-C₆ alkila;

R^{16} je odabrano od
 $-(C(R^{17a})_2)_2-X-R^{30}$,
 $-C(R^{17a})_2C(O)N(R^{16a})C(R^{17a})_2-X'-R^{31}$,
 $-C(R^{17a})_2[C(O)N(R^{16a})C(R^{17a})_2]_w-X-R^{31}$,
 $-(C(R^{17a})(R^{17})C(O)NR^{16a})_n-H$; i
 $-(C(R^{17a})(R^{17})C(O)NR^{16a})_m-C(R^{17a})(R^{17})-CO_2H$; gdje:

w' je 2 ili 3;

n' je 1-6;

m' je 1-5;

X je lanac od između 1 i 172 atoma gdje su atomi odabrani od ugljika i kisika i gdje lanac može da sadrži jednu, dvije, tri, ili četiri grupe odabrane od $-NHC(O)NH-$, i $-C(O)NH$ ugrađene tamo; i gdje je lanac po izboru supstituiran sa jednom do šest grupa nezavisno odabranih od $-CO_2H$, $-C(O)NH_2$, $-CH_2C(O)NH_2$, i $-CH_2CO_2H$,


X' je lanac od između 1 i 172 atoma gdje su atomi odabrani od ugljika i kisika i gdje lanac može da sadrži jednu, dvije, tri, ili četiri grupe odabrane od $-NHC(O)NH-$, i $-C(O)NH$ ugrađene tamo; i gdje je lanac po izboru supstituiran sa jednom do šest grupa nezavisno odabranih od $-CO_2H$, $-C(O)NH_2$, i $-CH_2CO_2H$, pod uvjetom da X' je drugačije od nesupstituiranog PEG;

R^{30} je odabrano od $-CO_2H$, $-C(O)NR^wR^x$, i $-CH_3$ gdje R^w i R^x su nezavisno odabrani od vodika i C_1 - C_6 alkila, pod uvjetom da kada X je sav ugljik, R^{30} je drugačije od $-CH_3$;

R^{31} je $-CO_2H$, $-C(O)NR^wR^x$, $-CH_3$, aleksa-5-SDP, i biotin;

svako R^{17a} je nezavisno odabrano od vodika, C_1 - C_6 alkila, $-CH_2OH$, $-CH_2CO_2H$, $-(CH_2)_2CO_2H$,

svako R^{17} je nezavisno odabrano od vodika, $-CH_3$, $(CH_2)_zN_3$, $-(CH_2)_zNH_2$, $-X-R^{31}$, $-(CH_2)_zCO_2H$, $-CH_2OH$, $CH_2CC\equiv H$, i $-(CH_2)_z$ -triazolil- $X-R^{35}$, gdje z je 1-6 i R^{35} je odabrano od $-CO_2H$, $-C(O)NR^wR^x$, CH_3 , biotina, 2-fluopiridina, $-C(O)-(CH_2)_2-C(O)O$ -vitamina E, $-C(O)O$ -vitamina E, i



pod uvjetom da je najmanje jedno R^{17} drugačije od vodika, $-CH_3$, ili $-CH_2OH$;

R^a , R^f , R^j , R^k , R^l , i R^m su vodik;

R^b i R^c su metil;

R^8 je odabrano od vodika i metila;

R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^8 , R^9 , R^{10} , R^{11} , i R^{12} su nezavisno odabrani od bočnog lanca prirodne amino kiseline i bočnog lanca ne-prirodne amino kiseline ili formiraju prsten sa odgovarajućom susjednom R grupom kao što je opisano ispod;

R^d je odabrano od vodika i metila, ili, R^d i R^4 , zajedno sa atomima za koje su vezani, formiraju prsten odabran od azetidina, pirolidina, morfolina, piperidina, piperazina, i tetrahidrotiazola; gdje svaki prsten je po izboru supstituiran sa jednom do četiri grupe nezavisno odabrane od amino, cijano, metil, halo, halometil, i hidroksi;


R^e je odabrano od vodika i metila, ili, R^e i R^5 , zajedno sa atomima za koje su vezani, formiraju prsten odabran od azetidina, pirolidina, morfolina, piperidina, piperazina, i tetrahidrotiazola; gdje svaki prsten je po izboru supstituiran sa jednom do četiri grupe nezavisno odabrane od amino, cijano, metil, halo, halometil, i hidroksi;

R^h je odabrano od vodika i metila, ili, R^h i R^8 , zajedno sa atomima za koje su vezani, formiraju prsten odabran od azetidina, pirolidina, morfolina, piperidina, piperazina, i tetrahidrotiazola; gdje svaki prsten je po izboru supstituiran sa jednom do četiri grupe nezavisno odabrane od amino, cijano, metil, halo, halometil, i hidroksi; i

R^i je odabrano od vodika i metila, ili, R^i i R^9 , zajedno sa atomima za koje su vezani odabran od azetidina, pirolidina, morfolina, piperidina, piperazina, i tetrahidrotiazola; gdje svaki prsten je po izboru supstituiran sa jednom do četiri grupe nezavisno odabrane od amino, cijano, metil, halo, halometil, i hidroksi.

17. Spoj iz patentnog zahtjeva 16, ili farmaceutski prihvatljiva sol istog, gdje

A je



n je 1;

R^{16} je $-(C(R^{17a})(R^{17})C(O)NR^{16a})_m-C(R^{17a})(R^{17})-CO_2H$;

svako R^{16a} je vodik;

m' je 2, 3, ili 4;

svako R^{17a} je vodik;


svako R^{17} je nezavisno odabrano od vodika, $-(CH_2)_2NH_2$, $-X-R^{31}$ i $-CH_2C\equiv CH$,




z je 4;




X je lanac od između 26 i 155 atoma gdje su atomi odabrani od ugljika i kisika i gdje lanac može da sadrži jednu, dvije, ili tri $C(O)NH$ grupe ugrađene tamo; i gdje lanac je po izboru supstituiran sa jednom ili dvije grupe nezavisno odabrane od $-CO_2H$, $-C(O)NH_2$, $-CH_2C(O)NH_2$, i $-CH_2CO_2H$; i


R^{31} je $-CH_3$, aleksa-5-SDP, i biotin.

18. Spoj prema patentnom zahtjevu 1 ili 16 odabran od:












1




2




3





5







5






5



































1



2














ili farmaceutske prihvatljive soli istog.



- 5 19. Spoj prema patentnom zahtjevu 1 odabran od:






































5






5






















i




- 5 ili farmaceutski prihvatljiva sol istog.
20. Spoj prema patentnom zahtjevu 1 odabran od:







5




5










5





5






[illegible][illegible]


•



















































i





5 ili farmaceutske prihvatajiva sol istog.


21. Spoj prema patentnom zahtjevu 1 odabran od:
























































1















Ili farmaceutske prihvatljive soli iste.




22. Spoj prema patentnom zahtjevu 1 odabran od:





























































5






5
















ili farmaceutski prihvatljiva sol istog.


23. Spoj prema patentnom zahtjevu 1 ili 16 odabran od:


















5






5

























































i




ili farmaceutski prihvatljiva sol istog.

24. Spoj prema patentnom zahtjevu 1 odabran od:











5









5

















































1






2




3










i







- 5 ili farmaceutski prihvatljiva sol istog.
25. Spoj prema patentnom zahtjevu 1 odabran od:


















































5






5















ili farmaceutski prihvatljiva sol istog.

26. Spoj prema patentnom zahtjevu 1 koje je



ili farmaceutski prihvatljiva sol istog.

27. Spoj iz patentnog zahtjeva 1 ili terapijski prihvatljiva sol istog za primjenu u poboljšanju, stimuliranju, i/ili povećanju imunog odgovora kod subjekta koji ima potrebu za istim.

28. Spoj ili terapijski prihvatljiva sol istog za primjenu prema patentnom zahtjevu 27 koja dalje obuhvaća administriranje dodatnog agensa prije, nakon, ili istovremeno sa spojem iz patentnog zahtjeva 1 ili terapijski prihvatljivom soli istog.

29. Spoj ili terapijski prihvatljiva sol istog za primjenu prema patentnom zahtjevu 28 gdje dodatni agens je antimikrobni agens, antivirusni agens, citotoksični agens, i/ili modifikator imunog odgovora.
30. Spoj ili terapijski prihvatljiva sol istog za primjenu prema patentnom zahtjevu 28 gdje dodatni agens je HDAC inhibitor.
- 5 31. Spoj ili terapijski prihvatljiva sol istog za primjenu prema patentnom zahtjevu 28 gdje dodatni agens je TLR7 i/ili TLR8 agonist.
32. Spoj iz patentnog zahtjeva 1 ili terapijski prihvatljiva sol istog za primjenu u inhibiranju rasta, proliferacije, ili metastaze stanica raka kod subjekta koji ima potrebu za istim.
- 10 33. Spoj ili terapijski prihvatljiva sol istog za primjenu prema patentnom zahtjevu 32 gdje je rak odabran od melanoma, raka bubrežnih stanica, skvamoznog ne-sitnostaničnog raka pluća (squamous non-small cell lung cancer - NSCLC), ne-skvamoznog NSCLC, kolorektalnog raka, kastracijsko-rezistentnog raka prostate, raka jajnika, raka želuca, hepatocelularnog raka, raka gušterače, raka skvamoznih stanica glave i vrata, raka jednjaka, gastrointestinalnog trakta i dojke, i hematoloških maligniteta.
- 15 34. Spoj iz patentnog zahtjeva 1 ili terapijski prihvatljiva sol istog za primjenu u liječenju infektivne bolesti kod subjekta koji ima potrebu za istim.
35. Spoj ili terapijski prihvatljiva sol istog za primjenu prema patentnom zahtjevu 34 gdje infektivna bolest je izazvana virusom.
36. Spoj ili terapijski prihvatljiva sol istog za primjenu prema patentnom zahtjevu 35 gdje virus je odabran od HIV, Hepatitis A, Hepatitis B, Hepatitis C, herpes virusa, i influence.
- 20 37. Spoj iz patentnog zahtjeva 1 ili terapijski prihvatljiva sol istog za primjenu u liječenju septičnog šoka kod subjekta koji ima potrebu za istim.